10M
Patients exposed to broad spectrum antibiotics
$45Bn
Annual economic burden associated with HAIs
$3Bn
Estimated ICU opportunity
$600M
Estimated Leukemia opportunity
Focused entry. Broader platform potential.
Our initial development programs focused on patient populations where antibiotic exposure, microbiome disruption, and infection risk converge.
ICU / Critical Care
HIGH-RISK POPULATIONS
Where antibiotic exposure, microbiome disruption and infection converge
Initial Focus ICU + Leukemia
Opportunity and Collaboration
Healthcare-associated infections remain a significant clinical and economic burden, particularly among vulnerable patients exposed to broad-spectrum antibiotics.
Antibiotic treatment can disrupt the gut microbiome, reducing its natural protective functions and creating an environment where potentially pathogenic organisms can proliferate.
KeepBio is developing a microbiome-based approach designed to help rebuild a healthy gut microbiome and support its natural protective functions.
Where KeepBio is focusing first
CRITICAL CARE
Patients receiving broad-spectrum antibiotics in the ICU represent an important opportunity to evaluate microbiome restoration as an additional strategy for supporting the microbiome’s natural protective functions.
HEMATOLOGY & ONCOLOGY
Patients undergoing intensive treatment for leukemia and other hematologic conditions frequently experience significant antibiotic exposure and microbiome disruption.
Partner with KeepBio to advance the science
KeepBio is seeking collaborations with hospitals, investigators, and clinical research organizations interested in studying microbiome restoration in vulnerable patient populations.
We welcome discussions about clinical studies, translational research, and real-world evidence generation.
IMMUNOCOMPROMISED
Patients with compromised immune systems may be particularly vulnerable to microbiome disruption and colonization by potentially pathogenic organisms.
✓
PROTECTED INNOVATION
Building a defensible microbiome platform
KeepBio’s technology and development approach are protected through a combination of patents and proprietary trade secrets, creating intellectual property protection around key elements of the platform and its application.
Areas of Interest
Antibiotic-associated microbiome disruption Gut colonization by potentially pathogenic organisms MDRO colonization and transmission Healthcare-associated infections Critical care and ICU populations
Leukemia and hematologic malignancies Hematopoietic stem cell transplantation Other immunocompromised patient populations Biomarkers of microbiome recovery Real-world and health-economic outcomes